Cite
HARVARD Citation
Clarke, D. et al. (2020). Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial. Lancet infectious diseases. 20 (4), pp. 455-466. [Online].